MAPK13 stabilization via m6A modification limits anti-cancer efficacy of rapamycin
J. Kim, Y. Chun, C. B. Ramirez, L. A. Hoffner, S. Jung, K. H. Jang, V. I. Rubtsova, C. Jang, G. Lee
This study shows that m6A modification of MAPK13 mRNA by the METTL3-METTL14-WTAP complex promotes its degradation, and rapamycin stabilizes MAPK13, which enhances anti-cancer effects when silenced.
bioRxiv · Aug 5, 2022Cancer Biology